Maxim raised the firm’s price target on Kazia Therapeutics (KZIA) to $20 from $15 and keeps a Buy rating on the shares. The company has made significant progress in developing paxalisib for triple-negative breast cancer and has read out consistently positive data across both TNBC and ER+/HER2-breast cancer, and while it’s early stage, the data thus far appears promising, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KZIA:
- Kazia Therapeutics’ paxalisib combination shows tumor reduction
- Kazia Therapeutics files to sell 232,956 American Depositary Shares for holders
- Two new option listings and nine option delistings on September 22nd
- Buy Rating for Kazia Therapeutics Driven by Promising Paxalisib Developments in Cancer Treatment
- Kazia Therapeutics Achieves Breakthrough in Breast Cancer Treatment with Paxalisib